Resolution of Serious Vaso-occlusive Pain Crises: Results From The Ongoing Phase 1/2 HGB-206 Group C Study of Lentiglobin for Sickle Cell Disease (SCD) Gene Therapy

被引：0

作者：

Mapara, Markus ^{[1
]}

Walters, Mark ^{[2
]}

Thompson, Alexis ^{[3
,4
]}

Kwiatkowski, Janet ^{[5
,6
]}

Krishnamurti, Lakshmanan ^{[7
]}

Aygun, Banu ^{[8
]}

Kasow, Kimberly ^{[9
]}

Rifkin-Zenenberg, Stacey ^{[10
]}

Schmidt, Manfred ^{[11
]}

Nnamani, Mauris ^{[12
]}

VanNest, Sara ^{[12
]}

Pierciey, Francis, Jr. ^{[12
]}

Miller, Alex ^{[12
]}

Chen, Ren ^{[12
]}

Kim, Dennis ^{[12
]}

Goyal, Sunita ^{[12
]}

Kanter, Julie ^{[13
]}

Tisdale, John ^{[14
]}

机构：

[1] Columbia Univ, Med Ctr, New York, NY USA

[2] UCSF Benioff Childrens Hosp Oakland, Oakland, CA USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[4] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL USA

[5] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA

[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Emory Univ, Childrens Healthcare Atlanta, Atlanta, GA 30322 USA

[8] Cohen Childrens Med Ctr, Queens, NY USA

[9] Univ N Carolina, Chapel Hill, NC 27515 USA

[10] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[11] GeneWerk GmbH, Heidelberg, Germany

[12] Bluebird Bio Inc, Cambridge, MA USA

[13] Univ Alabama Birmingham, Birmingham, AL USA

[14] NIH, Bldg 10, Bethesda, MD 20892 USA

来源：

BONE MARROW TRANSPLANTATION | 2021年 / 56卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O056

引用

页码：66 / 68

页数：3

共 44 条

[21] Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease [J].

Kanter, Julie ;

Walters, Mark C. ;

Hsieh, Matthew M. ;

Krishnamurti, Lakshmanan ;

Kwiatkowski, Janet ;

Kamble, Rammurti T. ;

von Kalle, Christof ;

Kuypers, Frans A. ;

Cavazzana, Marina ;

Leboulch, Philippe ;

Joseney-Antoine, Marcelyne ;

Asmal, Mohammed ;

Thompson, Alexis A. ;

Tisdale, John F. .

BLOOD, 2016, 128 (22)

[22] Interim Results from a Phase 1/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease [J].

Kanter, Julie ;

Walters, Mark C. ;

Hsieh, Matthew ;

Krishnamurti, Lakshmanan ;

Kwiatkowski, Janet L. ;

Kamble, Rammurti ;

von Kalle, Christof ;

Joseney-Antoine, Marcelyne ;

Pierciey, Francis J., Jr. ;

Shi, Weiliang ;

Asmal, Mohammed ;

Thompson, Alexis A. ;

Tisdale, John F. .

BLOOD, 2017, 130

[23] Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks [J].

Delicou, Sophia ;

El Rassi, Fuad ;

Andemariam, Biree ;

Abboud, Miguel R. ;

Kanter, Julie ;

Telen, Marilyn J. ;

Githanga, Jessie ;

Inati, Adlette ;

Idris, Ibrahim ;

Navani, Sunil ;

Wu, Eric ;

Eisenberger, Andrew .

BLOOD, 2024, 144 :179-180

[24] Initial Results from Study Hgb-206: A Phase 1 Study Evaluating Gene Therapy By Transplantation of Autologous CD34+Stem Cells Transduced Ex Vivo with the Lentiglobin BB305 Lentiviral Vector in Subjects with Severe Sickle Cell Disease [J].

Kanter, Julie ;

Walters, Mark C. ;

Hsieh, Matthew ;

Thompson, Alexis A. ;

Krishnamurti, Lakshmanan ;

Kwiatkowski, Janet ;

Kamble, Rammurti T. ;

von Kalle, Christof ;

Kuypers, Frans A. ;

Cavazzana, Marina ;

Leboulch, Philippe ;

Sandler, Laura ;

Soni, Sandeep ;

Tisdale, John F. .

BLOOD, 2015, 126 (23)

[25] Mechanism(s)-of-Action for Arginine Therapy in Children with Sickle Cell Disease and Vaso-Occlusive Pain: Results of a Pharmacokinetics/Pharmacodynamics Study [J].

Korman, Rawan ;

Hatabah, Dunia ;

Brown, Lou Ann ;

Harris, Frank ;

Bakhsi, Nitya ;

Rees, Christopher ;

Griffiths, Mark ;

Leake, Deborah ;

Dampier, Carlton ;

Morris, Claudia R. .

BLOOD, 2023, 142

[26] Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (vol 1, pg 1645, 2017) [J].

Field, J. J. ;

Majerus, E. ;

Gordeuk, V. R. .

BLOOD ADVANCES, 2017, 1 (23) :2058-2058

[27] The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated with Vaso-Occlusive Crises in Patients with Sickle Cell Disease: Results from the Sustain Trial [J].

Smith, Wally R. ;

Ataga, Kenneth I. ;

Saraf, Santosh L. ;

Adisa, Olufolake A. ;

Bailey, Miranda ;

Ramscar, Nicholas ;

Bonner, Ashley ;

Brown, Stephen ;

Pastor, Laura .

BLOOD, 2020, 136

[28] Real-World Data on the Occurrence of Vaso-Occlusive Crises (VOCs) in Patients with Sickle Cell Disease (SCD) and a High Baseline Disease Burden Treated with Crizanlizumab: Results from a Managed Access Program (MAP) [J].

Cancado, Rodolfo D. ;

Colombatti, Raffaella ;

Quarta, Antonella ;

Arcioni, Francesco ;

De Bonnett, Laurie ;

Soliman, Wesam ;

Sarkar, Rajendra ;

Silva Pinto, Ana Cristina .

BLOOD, 2021, 138

[29] Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study [J].

Liles, Darla ;

Smith-Whitley, Kim ;

Brown, R. Clark ;

Shah, Nirmish ;

Nair, Santosh M. ;

Tanaka, Chiaki ;

Bodla, Shankaranand ;

Sanchez-Olle, Gessami ;

Albers, Urs ;

Kanter, Julie .

BLOOD, 2020, 136

[30] An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070-A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia [J].

McCavit, Timothy L. ;

Krishnamurti, Lakshmanan ;

Hsu, Lewis L. ;

Quinn, Charles T. ;

Odame, Isaac ;

Alvarez, Ofelia A. ;

Driscoll, Catherine ;

Smith-Whitley, Kim ;

Rhee, Seungshin ;

Wun, Ted ;

Telen, Marilyn J. ;

Thackray, Helen .

BLOOD, 2013, 122 (21)

← 1 2 3 4 5 →